Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • UK partners with Eli Lilly on obesity plan
  • Policy / Pricing

UK partners with Eli Lilly on obesity plan

Pharmaphorum

The UK has teamed up with Eli Lilly on initiatives, backed with 85 million in funding, to expand access to treatment for obesity.

Metabolic & GLP-1

Read full story

pharminent June 29, 2026 (Last updated: June 29, 2026)

Pharmaphorum

The UK has teamed up with Eli Lilly on initiatives, backed with 85 million in funding, to expand access to treatment for obesity.

Metabolic & GLP-1

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Zymeworks cuts deal to buy Theravance for $929m in cash

Related Stories

  • Policy / Pricing

EFPIA report adds to pressures on EU drug pricing policy

pharminent June 24, 2026
  • Policy / Pricing

US launches probe of German ‘underpayment’ for medicines

pharminent June 19, 2026
  • Policy / Pricing

FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’

pharminent June 19, 2026

You May Have Missed

  • Policy / Pricing

UK partners with Eli Lilly on obesity plan

pharminent June 29, 2026
  • M&A / Deals

Zymeworks cuts deal to buy Theravance for $929m in cash

pharminent June 29, 2026
  • Clinical Data

BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit

pharminent June 29, 2026
  • Pipeline

Biogen trims Apellis pipeline and R&D team after $5.6bn takeover

pharminent June 29, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.